A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the clinical and laboratory toxicity of ganciclovir (GCV) and zidovudine (AZT) when given in combination.
Because recent information has shown AZT to be useful in treating AIDS, it is assumed that most patients with AIDS, and probably with AIDS related complex (ARC), will be receiving AZT. Because AZT is reported not to be active against cytomegalovirus (CMV), it is important to see if it is useful to give GCV along with AZT.
| Condition | Intervention |
|---|---|
|
Cytomegalovirus Infections HIV Infections |
Drug: Zidovudine Drug: Ganciclovir |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics Study Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase I Studies of the Combination of AZT and DHPG (Ganciclovir) in Patients With AIDS and Cytomegalovirus Infection |
| Estimated Enrollment: | 60 |
| Study Completion Date: | February 1990 |
Because recent information has shown AZT to be useful in treating AIDS, it is assumed that most patients with AIDS, and probably with AIDS related complex (ARC), will be receiving AZT. Because AZT is reported not to be active against cytomegalovirus (CMV), it is important to see if it is useful to give GCV along with AZT.
Patients are placed into one of four groups at entry into study according to their previous treatment:
I: Prior treatment with AZT up to the time of developing CMV infection and not requiring dose reduction of AZT for toxicity.
II: Prior treatment with AZT up to the time of developing CMV infection and requiring dose reduction of AZT for toxicity.
III: Prior therapy with GCV for CMV infection. These patients should already be in the maintenance phase, having completed a minimum of 2 weeks of induction therapy.
IV: No prior therapy with either AZT or GCV.
Treatment lasts 24 weeks and consists of two treatment plans:
A: Patients not previously treated with GCV are started on GCV for an additional 22 weeks. GCV is given as a 1-hour infusion. All patients are started on AZT at the lowest dose. B: For patients with chronic CMV disease who are receiving GCV maintenance, GCV is administered as a 1-hour infusion 5 days/week.
AZT is added and treatment with GCV is standardized prior to beginning of the study.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- Symptomatic therapy such as analgesics, antihistamines, antiemetics, and antidiarrheal agents, or other supportive therapy may be administered as deemed necessary by the responsible investigator. For fever, the following regimens should be used:
- If fever above 39.0 degrees C, antipyretic therapy will be administered employing aspirin, 650 mg orally every 4 hours x 3 doses, or until fever falls below 39.0 degrees C.
- If fever of higher than 39.0 degrees C occurs for 2 consecutive days, the patient may be premedicated with aspirin.
Exclusion Criteria
- Active alcohol or drug abuse.
Co-existing Condition:
Excluded:
- Patients with other life-threatening and uncontrolled opportunistic infections on enrollment.
Patients with the following prior conditions are excluded if they:
- Have other life-threatening and uncontrolled opportunistic infections on enrollment.
Prior Medication:
Excluded within 1 week of study entry:
- Systemic therapy with antimetabolite.
- Cytotoxic drug.
- Interferon.
- Immunologic modulators.
- Corticosteroids.
- Nucleoside analogs other than zidovudine (AZT).
- Excluded within 2 weeks of study entry:
- Therapy for any other opportunistic infections.
- Excluded within 2 months of study entry:
- Ribavirin.
Prior Treatment:
Excluded within 2 weeks of study entry (for treatment group I):
- Blood transfusion.
- Excluded within 1 month of study entry (for treatment groups II and III):
- Blood transfusion.
All patients must be:
- Able to provide informed consent.
- Likely to be available for follow-up for at least 4 months.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00000995
| United States, California | |
| Univ of California / San Diego Treatment Ctr | |
| San Diego, California, United States, 921036325 | |
| United States, New York | |
| Bellevue Hosp / New York Univ Med Ctr | |
| New York, New York, United States, 10016 | |
| Univ of Rochester Medical Center | |
| Rochester, New York, United States, 14642 | |
| Study Chair: | Reichman RC | |
| Study Chair: | Richman D | |
| Study Chair: | Hochster H |
More Information
Additional Information:
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00000995 History of Changes |
| Other Study ID Numbers: | ACTG 004 10980 |
| Study First Received: | November 2, 1999 |
| Last Updated: | February 15, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
AIDS-Related Opportunistic Infections Ganciclovir Drug Evaluation Drug Therapy, Combination |
Cytomegalovirus Infections Acquired Immunodeficiency Syndrome Zidovudine |
Additional relevant MeSH terms:
|
Infection Communicable Diseases HIV Infections Cytomegalovirus Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Herpesviridae Infections |
DNA Virus Infections Zidovudine Ganciclovir Ganciclovir triphosphate Antimetabolites Molecular Mechanisms of Pharmacological Action Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents |
ClinicalTrials.gov processed this record on September 27, 2016